Thursday Aug 21
Theravance Biopharma to Present at Investor Conferences in September 2014
Theravance Biopharma, Inc. announced today that Rick E Winningham, Theravance Biopharma's Chief Executive Officer, is scheduled to present at the following investor conferences in September 2014: Baird 2014 Health Care Conference The New York Palace, New York, New York Thursday, September 4, 2014 2:35 p.m. EDT The presentations will be webcast live ... (more)
Thursday Aug 21
Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market
Theravance is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years.
Mon Aug 18, 2014
Theravance (THRX) Announces Quarterly Earnings Results, Beats Estimates By $0.35 EPS
Theravance posted its quarterly earnings results on Monday. The company reported earnings per share for the quarter, beating the consensus estimate of by $0.35, American Banking News.com reports.
Sat Aug 16, 2014
Theravance VP Junning Lee Sells 53,424 Shares
Theravance VP Junning Lee unloaded 53,424 shares of Theravance stock on the open market in a transaction that occurred on Wednesday, August 13th.
Thu Aug 14, 2014
Theravance Lowered to Underperform at Robert W. Baird
In other Theravance news, SVP Bradford J. Shafer sold 28,156 shares of the stock in a transaction dated Tuesday, August 12th.
Theravance Biopharma, Inc. - 10-Q - Management's Discussion and...
This Report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Wed Aug 13, 2014
Theravance Biopharma, Inc. Reports Second Quarter 2014 Financial Results
Revenue for the second quarter of 2014 was $3.0 million. Net loss for the second quarter of 2014 was $58.2 million or $1.83 per share.
Theravance Sees Significant Drop in Short Interest
Theravance was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 21,928,363 shares, a decline of 7.1% from the July 15th total of 23,592,563 shares, Stock Ratings Network.com reports.
Fri Aug 08, 2014
Theravance Stock Rating Reaffirmed by Zacks
's stock had its "neutral" rating reiterated by Zacks in a research report issued on Friday.
Thu Aug 07, 2014
Theravance Inc - 10-Q - Management's Discussion and Analysis of...
The information in this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended , and Section 21E of the Securities Exchange Act of 1934, as amended.
Theravance Reports Increased Patient Access And High Confidence In Dividend
Yesterday, Theravance released its Q2 earnings update. Being still in the early days of its operations, the income statement was of less importance compared to the balance sheet, which was the first without Biopharma .
Wed Aug 06, 2014
Theravance Reports Second Quarter 2014 Financial Results
Royalties earned in the second quarter of 2014 were $3.3 million, which were partially offset by amortization of intangible assets of $2.6 million resulting in net royalty revenues of approximately $0.7 million from Glaxo Group Limited related to net sales of RELVAR /BREO ELLIPTA and ANORO ELLIPTA from GSK.
Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer
Mr. Aguiar plans to continue to serve as Theravance's Senior Vice President and Chief Financial Officer until his replacement is identified and appointed.
Tue Aug 05, 2014
Theravance (THRX) Scheduled to Post Earnings on Wednesday
Theravance is set to release its Q214 earnings data on Wednesday, August 6th. Analysts expect Theravance to post earnings of per share and revenue of $4.39 million for the quarter.